ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

In this interview, Glenn A. Hirsch MD, MHS, FACC and Alison L. Bailey MD, FACC discuss Top Takeaways from 2022: General Cardiology. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Martha Gulati MD MS FACC FAHA FASPC FESC and Alison L. Bailey MD, FACC, discuss the Top Takeaways from 2022: Preventive Cardiology. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Dipti Itchhaporia MD, FACC and Alison L. Bailey MD FACC discuss the Top Takeaways from 2022 in Interventional Cardiology. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Christopher M. Kramer MD, FACC and Alison L. Bailey, MD FACC discuss the Top Takeaways from 2022 in cardiovascular imaging. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Clyde W. Yancy MD, MSc, MACC, FAHA, MACP and Alison L. Bailey MD FACC, discuss the Top Takeaways from 2022: Heart Failure. Dr. Yancy discusses trials including DELIVER, TRANSFORM-HF, DCP, BRIGhtn, and the ACC/AHA/HFSA Guidelines.

Earlier detection of people at risk of HF would enable cardioprotection to be initiated earlier and damage avoided. Current imaging tools (eg. ejection fraction) are not sensitive enough to identify early disease. While GLS has been shown to predict outcomes, this study shows that its use improves the predictive power of the current definition of stage B HF. In this interview, Professor Tom Marwick  MBBS, PhD, MPH, FAHMS and John Gorcsan III MD, FACC discuss improving characterization of Stage A and B HF by adding strain. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In an effort to limit unnecessary testing and increase diagnostic yield, current major guideline recommendations recommend a risk-based strategy with deferred testing in low-risk patients, catheterization in high risk patients, and selective noninvasive testing for those at intermediate risk. To date, no randomized trial has explored the clinical efficacy and safety of any such strategy. In this interview, Pamela S Douglas MD, MACC and Anthony N. DeMaria MD, MACC discuss Real World Implications of 2021 AHA/ACC Chest Pain Guidelines: Modeling of Deferred Testing Recommendations in the PROMISE Trial. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Thiazides are recommended first line agents for the treatment of hypertension.  They have been demonstrated to lower cardiovascular disease.  Which thiazide to choose has been a long-standing issue. In this interview, Areef Ishani MD, MS and W. Douglas Weaver MD, MACC discuss AHA Late-Breaker: DCP – Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients with Hypertension. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Ultrasound can make it easier for cardiologists to do procedures including angioplasty or stenting when femoral artery is used. In this interview, Sanjit Jolly MD, MSc and Matt Cavender MD MPH, FACC, with Sun Moon Kim MD FSCAI, FACC, discuss Routine Ultrasound for Vascular Access. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In this interview, Martin Halle MD and Steven E. Nissen MD, MACC discuss a recent piece in JACC: Exercise for Primary and Secondary Prevention of Cardiovascular Disease.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

Any person with a smartphone can screen him- or herself for treatment-relevant atrial fibrillation - the world's most important arrhythmia. This could have huge impact on the prevention of stroke. In this interview, Axel Bauer MD and Thomas F. Deering MD, FACC, with Sun Moon Kim MD, FSCAI, FACC, discuss ESC Late-Breaker: eBRAVE-AF: Smartphone-based AF screening.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

This subgroup analysis from the MASTER-DAPT trial demonstrates that in high-bleeding risk patients with acute or recent myocardial infarction it is safe to stop DAPT 1 month after stenting and that this strategy provides a reduction in bleeding risk. In this interview, Pieter C. Smits MD, PhD, FESC and Sidney C. Smith Jr. MD, MACC, with Jeffrey Hsu MD, PhD, discuss a recent piece from JACC: Abbreviated Antiplatelet Therapy after Coronary Stenting in Patients with Myocardial Infarction at High Bleeding Risk.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

In the DANCAVAS Trial, researchers found a remarkable reduction in death of any cause, and this might be a game changer in prevention of cardiovascular diseases. In this interview, Axel Cosmus Pyndt Diederichsen MD and Clyde W. Yancy MD, MSc, MACC, FAHA, MACP, FHFSA, FASPC (Hon.) discuss ESC Late-Breaker: DANCAVAS: screening and intervention to prevent cardiovascular disease. Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL

As we age we are increasingly challenged by physical activities. Regular exercise is an essential medicine to maintain a level of function that encompasses simple activities as we age. On the flip side, a lack of exercise leads to a lack of heart conditioning that can contribute to a lack of heart capacity resulting in shortness of breath and heart failure with stressors such as illness or physical activity. Does the concept of exercise deficiency apply to all cases of HFPEF? In this interview, Professor Andre La Gerche MD, PhD and Christopher M. Kramer MD, FACC discuss a recent piece in JACC: HFpEF as an Exercise Deficiency Syndrome.

Marfan Syndrome is a rare genetic heart disease, but still affects over a million people worldwide. It causes swelling of the main blood vessel of the heart, which can even tear if major surgery is not performed - usually when the patient is in their 20s or 30s. Researchers form Oxford University worked with teams all over the world to combine results from several trials involving almost 1500 patients - the most powerful study of its kind - and found that two widely available medicines, angiotensin receptor blockers and beta-blockers, work both separately and in combination to slow the rate of expansion of the blood vessel, potentially delaying the need for surgery and the risk of tearing by a decade or more if the drugs are taken together long term. In this interview, Alex Pitcher, MD and William E. Boden MD, FACC, FAHA, with Sun Moon Kim MD FSCAI FACC, discuss the ESC Late-Breaker: MTT: Assessing the Effects of ARBs and Beta-Blockers in Marfan Syndrome.

INOCA and MINOCA are conditions with high risk of cardiac events and frequent persistent ischemic symptoms, and aggressive intervention is needed to reduce risk and symptom burden. This episode will review the data on contemporary treatment of INOCA and MINOCA and discuss additional strategies beyond the data and future directions. In this interview, Jamieson Bourque, MD., MHS., FACCE and Magnus Ohman MD, FACC, with Michelle D. Kelsey MD, ask if there is evidence for treatment, and discuss data-driven management of in-patients with INOCA and MINOCA.

We have never had a symptoms-based guideline before. Why was it time for these new Chest Pain Guidelines? How does shared decision-making come into the assessment of chest pain? Is anatomic or functional testing preferred in the evaluation or acute chest pain or stable chest pain? In this interview, Martha Gulati MD MS FACC FAHA FASPC FESC and Christopher M. Kramer MD, FACC, with Nosheen Reza MD, discuss the top controversies behind the Chest Pain Guideines.

In this interview, Francesco Franchi, MD and Spencer B. King III, MD, MACC, with Matt A. Cavender MD, MPH, FACC, discuss how to make the best choice when selecting an oral P2Y12 inhibitor post-MI.

The highly anticipated newest iteration of the Chronic Heart Failure Guidelines are finally here. What updates are most important to clinicians, and how can they be most effectively implemented in clinical practice? In this interview, Michelle Kittleson MD, PhD and Clyde W. Yancy MD, FACC, with Hilary Shapiro, MD MSc, discuss how to implement the new HF Guidelines into your practice.

Any of us could suffer a nonfatal cardiac arrest. Sudden cardiac arrest is not limited to patients with heart disease. Even athletes could have a sudden and unexpected cardiac arrest. We must be prepared as society (external defibrillators and CRP) but also as cardiologists (to perform the correct studies). In this interview, Manlio Marquez, MD, FACC and Jeroen J. Bax PhD, MD, FACC, with Zain Ul Abideen Asad MD, discuss how one should perform an investigation of a survivor of sudden cardiac arrest.

What do the new Chest Pain Guidelines say about additional noninvasive testing for low risk and intermediate risk patients? Is relief of chest pain with nitroglycerin diagnostic of myocardial ischemia? In this interview, Debabrata Mukherjee, MD, MS and Jeroen J. Bax PhD, MD, FACC, with Jonathan R. Salik, MD, discuss these questions and other top takeaways for the practicing clinician: from the Chest Pain Guidelines.

Death due to pulmonary embolism remains high, despite increased attention and advances in various medications and treatment techniques. Surgical treatment of acute PE is safe and highly effective at saving lives. In this interview, Joshua B. Goldberg, MD and C. Noel Bairey Merz MD, FACC, with Michelle D. Kelsey MD, discuss Modern Managment of High-Risk PE.

Peri-partum cardiomyopathy is a form of heart failure affecting young mothers during later stages of pregnancy or early post-partum. Medical management should be tailored to improving the mother's health while ensuring safety of the baby. Which of the currently available heart failure drugs are safe in pregnancy and during breast feeding? What are the outcomes of women with peripartum cardiomyopathy, who undergo LVAD implantation or heart transplantation? In this interview, Dharini Ramu, MD, FACC and Spencer B. King III, MD, MACC, with Yuvraj Chowdhury MD, discuss Medical and Advanced Heart Failure Therapies in Peri-partum cardiomyopathy: A Cardiologist's Perspective.

Women with preeclampsia and related hypertensive disorders of pregnancy have increased risk of heart disease compared with women who experienced uncomplicated pregnancy. Women should ensure treating clinicians know their reproductive history, and clinicians should work to aggressively prevent and treat development of cardiovascular risk factors in women with a history of preeclampsia. In this interview, Michael Honigberg, MD, MPP, FACC and Glenn A. Hirsch MD, MHS, FACC, with Yuvraj Chowdhury MD, discuss Pre-Eclampsia: Maternal Red Flag of Risk.

The United States is the only developed country with rising rates of death during pregnancy and up to one year postpartum. The maternal mortality crisis is disproportionately impacting women of color, specifically Black women who are 3 times as likely to die. This is regardless of education, income or profession and most notably is as a result of psychosocial stressors, including racism. In this interview, Rachel M Bond, MD, FACC and Alison L. Bailey, MD FACC, with Michelle D. Kelsey MD, discuss Black Maternal Health: A Call to Action and Implications for Prevention.

When can COVID survivors return to play? In this interview, Nicole Martin Bhave, MD, FACC, FASE and Eugene Ho-Joon Chung, MD, discuss the ACC Expert Consensus Decision Pathway on COVID-19: Return to Play.

Post-COVID, cardiovascular symptoms may persist or emerge more than 4 weeks after infection. Identifying people with cardiovascular disease sequelae is an important first step. However, many people have cardiovascular syndromes that are not easily identified on standard cardiac testing. More research is needed to better understand these syndromes. In the meantime, we need to come together as a community to share best practices and maximally support patients so that they can return to their daily lives. In this interview, Erica Sarah Spatz, MD, FACC and Alison L. Bailey, MD, FACC, with Tiffany Y. Hu, MD, discuss ACC Expert Consensus Decision Pathway on COVID-19: Post-acute Sequelae.

Attack of the heart muscle by the immune system (myocarditis) is a rare but serious complication of SARS-CoV-2 infection, and an even more rare complication of COVID-19 mRNA vaccination. In this interview, Larry A. Allen, MD, MHS, FACC and Tyler J. Gluckman, MD, FACC, FAHA, discuss the ACC Expert Consensus Decision Pathway on COVID-19: Myocarditis.

Chronic inflammatory diseases are associated with accelerated atherosclerosis. Psoriasis in particular accelerates the formation of high risk coronary plaque which drives heart attack and stroke. Providers and patients need to be aware of these associations. In this interview, Nehal N. Mehta, MD MSCE and W. Douglas Weaver MD, MACC, with Matt A. Cavender MD, MPH, FACC, discuss Inflamed! Populations at Risk for Inflammation Associated CVD.

Which changes to the ACC/AHA/SCAI Coronary Artery Revascularization Guidelines will have the greatest impact to the patient? Which of the published “Top Ten Take-Away Messages” is most important? In this interview, Jacqueline E. Tamis-Holland, MD, FACC, FAHA, FSCAI and Roxana Mehran MD, FACC, with Yuvraj Chowdhury MD, discuss Most Significant Changes from the Prior Coronary Artery Revascularization Guidelines.

What is clinical problem with regard to leaflet thrombosis after TAVR, and what are the main findings of the ADAPT-TAVR trial? In this interview, Duk-Woo Park, MD and Sun Moon Kim MD, with Zaid I. Almarzooq MBBCh, discuss Late Breaker: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial.

In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.

Suzanne Oparil, MD, FACC, FAHA, FASH, FAPS and Nanette Kass Wenger MD, MACC, discuss ACC.22 Late Breaker: Antihypertensive Therapy For Mild Chronic Hypertension Improves Pregnancy Outcomes: A Pragmatic Multicenter RCT.

In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.

This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor. In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Clinicians often recommend dietary sodium reduction for almost all their patients with HF. Whether or not this practice should continue remains an uncertain question in almost every clinic visit. We spend a fair amount of time counselling patients on this, and patients want to know if they need to undertake a full change in their diet to improve how they feel or function, and if this changes will increase or decrease the chance of being in the hospital again. In this interview, Justin A. Ezekowitz, MBBCh, MSc and Steven E. Nissen MD, MACC, with Yuvraj Chowdhury MD, discuss Late Breaker: SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure.

Heart failure patients experience exercise intolerance and functional limitation every day. While the targeting of functional capacity is an important unmet need, this study found that the change in peak oxygen uptake did not differ between patients taking omecamtiv mecarbil and placebo. How do current guideline-directed medical therapies for heart failure impact exercise capacity? How does omecamtive mecarbil differ from other heart failure pharmacotherapies? In this interview, Gregory Lewis, MD and Jeroen J. Bax PhD, MD, FACC, with Ioannis Mastoris, MD, MPHcand, discuss Late Breaker: METEORIC-HF: The Effect Of Omecamtiv Mecarbil On Exercise Tolerance In Patients With Chronic HFrEF.

Heart failure patients are generally multi-morbid and at risk for hyperkalemia, which makes treatment with life-saving therapies like RAASi difficult and leads to compromised medical treatment and in turn poor outcomes. This trials showed that with the use of patiromer, one can simultaneously lower the risk of hyperkalemia and increase optimal medical therapy for heart failure with reduced ejection fraction. In this interview, Javed Butler, MD MPH MBA, Anthony N. DeMaria MD, MACC, with Ioannis Mastoris, MD, MPHcand, discuss the Late Breaker: DIAMOND trial: Patiromer For The Management Of Hyperkalemia In Subjects Receiving Renin-angiotensin-aldosterone System Inhibitor Medications For Heart Failure With Reduced Ejection Fraction.

TTR amyloidosis is increasingly recognized as a cause of diastolic heart failure and as much more common than previously thought. There are proven and investigational therapies that can slow or possibly stop this disease. In this interview, Rodney H. Falk, MD, FACC and Alison L. Bailey, MD FACC, with Jonathan R. Salik, MD, discuss Screening for Transthretin Amyloid Cardiomyopathy in Everyday Practice.

Genetics can establish a baseline lifelong trajectory for cardiovascular disease risk for everyone. Learn the latest about testing, actionability, and limitations as well as future directions. In this interview, Pradeep Natarajan, MD, MMSc and Steven E. Nissen, MD, MACC, with Manuel Rivera Maza, MD, discuss When Is Genetic Testing Helpful?

In this interview, Benjamin D. Levine, M.D., FACC, FAHA, FACSM and Richard A. Chazal MD, MACC, with Arav Jhand MD, discuss athletes with underlying coronary artery disease: Special Considerations in Cardiovascular Screening, Evaluation and Management.

What digital and wearable technologies are patients using to change their lifestyle behaviors? What is the clinician's role in helping patients to use wearables and digital tools to help them live healthier lives, and what are the benefits? In this interview, Elizabeth A. Jackson, MD, MPH, FAHA, FACC and Roger S. Blumenthal MD, FACC discuss Helping Patients Improve Lifestyle Behavior in the Digital Era.

Cardiac amyloidosis is an often overlooked and thus misdiagnosed form of a restrictive cardiomyopathy in which delayed diagnosis is associated with significant morbidity and mortality. Immunoglobulin light chain (AL) cardiac amyloidosis is the most deadly from of cardiac amyloidosis but significant progress has been made in treatment with the first FDA approved therapy for this condition - daratumumab. In this interview, Mathew Maurer, MD and Stephen J. Nicholls, MBBS, PhD, FACC, with Yuvraj Chowdhury, MD, discuss Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis--Focus on AL.

It is important that patients with reduced heart function are treated with drugs that have been documented to prolong survival. In this interview, Finn Gustafsson, MD, PhD and Michelle Kittleson MD, FACC, along with Michael Mikolaj MD, MPH, FACC, discuss What Should Optimal Medical Therapy Look Like Prior to Intervention?

After a heart attack, levels of blood lipids such as low-density lipoprotein cholesterol (LDL-C) may influence the risk of further cardiovascular events. In this analysis, we determined that even when LDL-C levels are controlled with a statin, elevated levels of another blood lipid called lipoprotein(a) are associated with an increased risk of further cardiovascular events and a benefit of treatment with the PCSK9 inhibitors. In this interview, Gregory G. Schwartz, MD, PhD and Glenn A. Hirsch MD, MHS, FACC, with Lindsay Panah, MD, discuss Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients with Nominally Controlled LDL-Cholesterol.

Is atrial fibrillation ablation a "slam dunk" for athletes? When would a clinician favor pharmacotherapy? In this episode, Michael S. Emery, MD, MS, FACC debates Mark S Link, MD on Atrial Fibrillation Management in Athletes, moderated by Alison L. Bailey, MD FACC.